Expert Review of Anti-infective Therapy最新文献_第10页

Clinical utility of procalcitonin in implementation of procalcitonin-guided antibiotic stewardship in the South-East Asia and India: evidence and consensus-based recommendations 在东南亚和印度实施降钙素指导下的抗生素管理中降钙素的临床效用：证据和基于共识的建议

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-12-19 DOI: 10.1080/14787210.2023.2296066

Andrea Lay-Hoon Kwa, Brigitte Rina Aninda Sidharta, Do Ngoc Son, Kapil Zirpe, Petrick Periyasamy, Rongpong Plongla, Subramanian Swaminathan, Tonny Loho, Vu Giap, Anucha Apisarnthanarak

引用次数: 0

Low-risk penicillin allergy delabeling: a scoping review of direct oral challenge practice, implementation, and multi-disciplinary approaches 低风险青霉素过敏脱标：直接口服质疑实践、实施和多学科方法的范围综述

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-12-14 DOI: 10.1080/14787210.2023.2296068

Elise Mitri, Gemma Reynolds, Catherine J Hornung, Jason A Trubiano

引用次数: 0

Immunocompromised patients and COVID-19: how do we protect those most at risk? 免疫力低下的患者与 COVID-19：我们该如何保护高危人群？

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-12-14 DOI: 10.1080/14787210.2023.2296067

Jochen Schneider, Johanna Erber, Lutz Renders, Christoph D. Spinner

引用次数: 0

Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice. 多卢替拉韦+拉米夫定和比替拉韦/恩曲他滨/替诺福韦-阿拉芬酰胺在HIV感染的早期抗逆转录病毒治疗中的比较：临床实践的初步结果。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-11-06 DOI: 10.1080/14787210.2023.2279719

Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long

{"title":"Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice.","authors":"Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long","doi":"10.1080/14787210.2023.2279719","DOIUrl":"https://doi.org/10.1080/14787210.2023.2279719","url":null,"abstract":"Background: The efficacy and safety of dolutegravir+lamivudine (DTG +3TC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have been demonstrated in clinical trials of treatment-naïve therapy. However, real-life data are lacking. We investigated and compared the virological outcomes and safety of DTG + 3TC with BIC/FTC/TAF in an adult cohort of people living with HIV (PLWH).Research design and methods: We performed a retrospective cohort analysis of PLWH who were naïve to antiretroviral therapy and initiated the antiretroviral regimen of DTG + 3TC or BIC/FTC/TAF from January 2020 to March 2022. Treatment effectiveness, defined as the capability of treatment to achieve viral suppression (viral load < 50 copies/mL), was analyzed. Changes in immunology, metabolism, liver and renal function after 48 weeks of treatment were evaluated.Results: At 48 weeks, both groups showed high viral suppression, with 82.4% (108/131) and 89% (129/145) of the patients in the BIC/FTC/TAF and DTG + 3TC groups, respectively, having viral suppression (OR = 0.58, 95% CI: 0.29-1.15, P = 0.3). No differences existed in immunology, metabolism, liver and renal function; however, BIC/FTC/TAF led to greater weight gain.Conclusions: Both optimization strategies showed high tolerability in antiretroviral therapy-naïve patients, with no differences in virological efficacy; however, BIC/FTC/TAF may be related to the risk of weight gain risk. Further research is required to evaluate this problem.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials. 加拿大的医院获得性细菌性肺炎（HABP）和呼吸机相关细菌性肺炎：治疗更新和新型静脉抗菌药物的作用。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-10-09 DOI: 10.1080/14787210.2023.2268287

Coleman Rotstein, Joseph P Lynch, George G Zhanel

{"title":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials.","authors":"Coleman Rotstein, Joseph P Lynch, George G Zhanel","doi":"10.1080/14787210.2023.2268287","DOIUrl":"10.1080/14787210.2023.2268287","url":null,"abstract":"Introduction: Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) continue to be common infections causing significant morbidity and mortality worldwide. The timely initiation of empiric antimicrobial therapy is essential. In this paper, we provide a focused expert opinion on the current and potential empiric antimicrobial treatment options in HABP and VABP in Canada influenced by antimicrobial resistance impacting the use of older agents as well as available new intravenous (IV) antimicrobials.Areas covered: The authors discuss treatment options for HABP and VABP in Canada. In addition, we focus on the potential role of new IV antimicrobials recently introduced to Canada. A literature search of HABP and VABP treatments was performed via PubMed (up to March 2023), using the following key words: monotherapy, combination therapy, aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, penicillins as well as amoxicillin/clavulanate, ceftobiprole, ceftolozane/tazobactam, dalbavancin, and fosfomycin.Expert opinion: Empiric antimicrobial treatment for HABP and VABP in Canada continues to focus on both the severity of illness and the presence/absence of patient risk factors for antimicrobial resistance. The role of new IV antimicrobials in the empiric treatment for HABP and VABP depends on their antimicrobial activity and published data on efficacy and safety and influenced by Health Canada-approved indications.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Point prevalence probing of antimicrobial prescription patterns from a developing country. 发展中国家抗菌药物处方模式的点流行率调查。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-09-15 DOI: 10.1080/14787210.2023.2259098

Nazia Khursheed, Qadeer Ahsan, Salima Rattani, Madeeha Fatima, Ali Raza, Saba Tariq, Tauqeer Mustafa, Kamran Ahmed, Sadia Iqbal, Sibgha Zulfiqar, Syed Masroor Ahmed, Ghulam Fatima, Shehzad Akbar Khan, Farman Ullah, Rana Altaf Ahmed, Saba Jamal

{"title":"Point prevalence probing of antimicrobial prescription patterns from a developing country.","authors":"Nazia Khursheed, Qadeer Ahsan, Salima Rattani, Madeeha Fatima, Ali Raza, Saba Tariq, Tauqeer Mustafa, Kamran Ahmed, Sadia Iqbal, Sibgha Zulfiqar, Syed Masroor Ahmed, Ghulam Fatima, Shehzad Akbar Khan, Farman Ullah, Rana Altaf Ahmed, Saba Jamal","doi":"10.1080/14787210.2023.2259098","DOIUrl":"10.1080/14787210.2023.2259098","url":null,"abstract":"Background: Irrational use of antibiotics intensifies resistance and jeopardizes advances made in modern medicine. We aimed to conduct a baseline gap analysis survey on antibiotic prescription practices across Pakistan.Research design and methods: This multi-centered cross-sectional survey was conducted at six public sector tertiary care hospitals from February 2021 to March 2021. Data related to various variables including hospital infrastructure, policies and practices, monitoring and feedback, and epidemiological, clinical, and antibiotic prescription for surveyed patients was collected using World Health Organization (WHO) Point Prevalence Survey (PPS) methodology.Results: In a survey of 837 inpatients, 78.5% were prescribed antibiotics. Most commonly prescribed antimicrobial was ceftriaxone (21.7%), followed by metronidazole (17.3%), cefoperazone-sulbactam (8.4%), amoxicillin-clavulanate (6.3%), and piperacillin/tazobactam (5.9%). Surgical prophylaxis (36.7%) and community-acquired infections (24.7%) were the main reasons for antibiotic prescriptions. Single antibiotics were given to 46.7% of patients, 39.9% received a combination of two antibiotics, and 12.5% were prescribed three or more antibiotics. Among six hospitals surveyed, two had drug and therapeutic committees, three had infection prevention and control committees, and one had an antibiotic formulary.Conclusion: Findings demonstrate high consumption of broad-spectrum antimicrobials and emphasize the importance of expanding antimicrobial stewardship programs among hospitals. Mentoring clinical teams could help rationalize antimicrobial use.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10245623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the UK set to be hepatitis C free? 英国将无丙型肝炎吗?

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-09-11 DOI: 10.1080/14787210.2023.2255751

Maria Fernanda Guerra-Veloz, Riham Soliman, Kosh Agarwal

引用次数: 0

Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis. 部分抗病毒药物对COVID-19患者医疗保健利用的影响:系统综述和荟萃分析

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-09-05 DOI: 10.1080/14787210.2023.2254491

Bincai Wei, Ruhao Zhang, Huatang Zeng, Liqun Wu, Rongxin He, Junyao Zheng, Hao Xue, Jinlin Liu, Fengchao Liang, Bin Zhu

{"title":"Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis.","authors":"Bincai Wei, Ruhao Zhang, Huatang Zeng, Liqun Wu, Rongxin He, Junyao Zheng, Hao Xue, Jinlin Liu, Fengchao Liang, Bin Zhu","doi":"10.1080/14787210.2023.2254491","DOIUrl":"https://doi.org/10.1080/14787210.2023.2254491","url":null,"abstract":"Background: We aimed to assess the impact of antiviral drugs (fluvoxamine,remdesivir, lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care utilization (HCU) inCOVID-19 patients. We summarized findings from randomized controlledtrials (RCTs) and observational studies.Methods: We systematically searched four medical databases (PubMed, Web of Science, Embase, Cochrane Library) for COVID-19 studies up to February 15, 2023. A comprehensive review, meta-analysis, sensitivity analysis, and subgroup analysis were conducted. Pooled effects with 95% confidence intervals (CIs) were calculated for antiviral drugs' impact on hospitalization, mechanical ventilation (MV), and intensive care unit (ICU) outcomes.Results: Our analysis included 34 studies (584,978 patients). Meta-analysisindicated potential benefits: remdesivir and molnupiravir potentiallyreduced MV risk, and NRV/r correlated with lower hospitalizationrates. However, LPV/r did not notably curb HCU. Remdesivir waspreferable for high-risk COVID-19 patients, while molnupiravir andNRV/r were recommended for those aged 60 and above.Conclusion: Remdesivir, molnupiravir, and NRV/r may reduce HCU during the COVID-19 pandemic. However, due to limited study details and significant heterogeneity in effect estimates, further precise evidence is crucial, especially concerning emerging variants.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10153959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Langya henipavirus outbreak. 狼牙henipavirus爆发。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-27 DOI: 10.1080/14787210.2023.2260561

Vivek P Chavda, Vasso Apostolopoulos, Ranjit Sah

引用次数: 0

Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19. Nirmatrevir和利托那韦联合用药：新冠肺炎的抗病毒治疗。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-01 DOI: 10.1080/14787210.2023.2241638

Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, Rajesh Sonti

{"title":"Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19.","authors":"Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, Rajesh Sonti","doi":"10.1080/14787210.2023.2241638","DOIUrl":"10.1080/14787210.2023.2241638","url":null,"abstract":"Introduction: The emergence of the Omicron SARS-CoV-2 variant of concern in late November 2021 presaged yet another stage of the COVID-19 pandemic. Paxlovid, a co-packaged dosage form of two antiviral drugs (nirmatrelvir and ritonavir) developed by Pfizer, received its first FDA Emergency Use Authorization (EUA) and conditional marketing by European Medical Agency in patients at high risk of developing severe COVID-19.Areas covered: We reviewed the timeline of the drug nirmatrelvir from its discovery to authorization by FDA. After 1 year of its authorization, numerous studies and reports on paxlovid's use and post-use consequences are available. This review summarizes the complete journey of paxlovid from its development, preclinical studies, clinical trials, regulatory approvals, ongoing clinical trials, and safety measures, followed by discussions on recent updates on drug-drug interactions, adverse effects, and relapse of COVID-19.Expert opinion: Paxlovid, a new oral antiviral therapy for COVID-19, has shown promising results in clinical trials and has the potential to be effective against the pandemic, particularly for individuals at high risk of severe illness. Comorbidity usage and pharmacovigilance will play a significant stake in the future of paxlovid development. Second-generation Mpro inhibitors play an important role in the upcoming problems associated with COVID-19.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10594372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1